AcelRx Pharmaceuticals, a California-based privately-held pharmaceutical company, announced the hiring of Nigel Ray as VP, business development. Ray will lead AcelRx's partnering efforts for mid- and late-stage products, and report to Thomas Schreck, CEO. Ray was most recently VP, business development at Limerick BioPharma.
Sundia MediTech, a pharmaceutical contract research organization, appointed Charles Maher to SVP, sales and marketing. Maher was previously EVP, global sales and marketing at Azopharma Product Development Group, a CRO based in Florida. In his new role, Maher will be responsible for global business development, and will report to Sundia chairman and CEO Xiaochuan Wang.
Lannett Company, a generics manufacturer, appointed Keith Ruck as VP, chief financial officer, reporting to Arthur Bedrosian, president and CEO. Buck will handle all accounting, treasury and investor relations, as well as assist in new business development and M&A activities. Ruck was most recently VP, finance, at Maax KSD Corporation.